PCG
EWTX icon

Private Capital Group’s Edgewise Therapeutics EWTX Stock Holding History

Private Capital Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-151
Closed -$2K – 1952
2022
Q1 		$2K Buy
+151
New +$1.94K ﹤0.01% 1777

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Private Capital Group's EWTX Position: Q2 2022 in Review

Private Capital Group sold out of Edgewise Therapeutics (EWTX) in Q2 2022, closing a stake of 151 shares — an estimated $2K sold.

Private Capital Group first reported a position in EWTX in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 78 funds tracked by Wall St. Rank hold EWTX as of Q2 2022.

  • Private Capital Group reported no remaining Edgewise Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Private Capital Group sold 151 Edgewise Therapeutics shares in Q2 2022, an estimated $2K.
  • Private Capital Group first reported a position in Edgewise Therapeutics in Q1 2022 and held it in 1 quarter.
  • Private Capital Group's Edgewise Therapeutics position peaked at $2K in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.